Oncolix Sponsors Additional Research with MD Anderson Cancer Center
January 31 2018 - 7:30AM
HOUSTON, Jan. 31, 2018 (GLOBE NEWSWIRE) --
Oncolix, Inc., (OTCQB:ONCX) announced today that the Company has
sponsored additional research with MD Anderson Cancer Center. The
research will evaluate ProlantaTM for the potential
treatment of additional gynecological cancers, in particular
uterine cancer. Previous research funded at the MD Anderson Cancer
Center resulted in the discovery of the mechanism of action of
ProlantaTM (autophagy) and preclinical evidence of
efficacy in ovarian cancer.
“Because Prolanta has the potential to treat all
gynecological cancers, it is only fitting that we expand our focus
to uterine cancer,” said Michael T. Redman, chief executive officer
of Oncolix. “Like ovarian cancer, more than 80% of uterine cancer
cells overexpress prolactin receptors, which are the molecular
target for ProlantaTM. Similarly, the unmet medical
needs for uterine cancer are similar to ovarian cancer.”
Prolanta™ is being evaluated in an open-label
dose escalation Phase 1 clinical trial in patients with advanced
ovarian cancer. Patients are divided into three dosing groups, or
cohorts. Each sequential cohort will evaluate a higher dose of
Prolanta™. Patients will be evaluated over a 99-day period. Initial
dosing for 28 days is followed by a two-week safety assessment
period, and then continues for an additional 56 days if no
toxicities are observed. The first cohort, treated with the lowest
dose, was completed, and has shown no serious adverse events or
dose-limiting toxicity. Earlier this January, the Company announced
it is now recruiting the mid-dose patients for this trial. For more
information about the Phase 1 clinical trial please visit:
https://clinicaltrials.gov/ct2/show/NCT02534922?term=Prolanta&rank=1
About Oncolix
Oncolix is a clinical-stage biotechnology
company developing Prolanta™ for the treatment of ovarian, uterine,
breast and other cancers. The Company has a US FDA-cleared IND to
commence human testing of Prolanta™ in its first indication, the
treatment of ovarian cancer. This Phase 1 clinical trial is
currently in progress. Prolanta™ is a prolactin receptor antagonist
(or blocker) that has demonstrated efficacy in xenograft models
through a unique mechanism of action, autophagy. In addition to
ovarian cancer, there is strong preclinical evidence Prolanta™ may
be effective in breast, uterine, prostate and other cancers. In the
current Phase 1 dose-escalation safety trial for the treatment of
ovarian cancer, to date there have been no observed serious adverse
events and no dose-limiting toxicities. The FDA has approved the
designation of Prolanta™ as an Orphan Drug for the treatment of
ovarian cancer, which may result in reduced filing fees (currently
$2 million), federal tax credits and marketing exclusivity.
Forward-Looking Statements
This press release above may contain
forward‐looking statements about the business, financial condition
and prospects of the Company. Forward looking statements can be
identified by the use of forward-looking terminology such as
“believes,” “projects,” “expects,” “may,” “goal,” “estimates,”
“should,” “plans,” “targets,” “intends,” “could,” or “anticipates,”
or the negative thereof, or other variations thereon, or comparable
terminology, by discussions of strategy or objectives.
Forward-looking statements relate to anticipated or expected
events, activities, trends or results. Because
forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to risks and
uncertainties.
Although the Company believes that the
expectations reflected in forward-looking statements are
reasonable, there can be no assurances that such expectations will
prove to be accurate. Security holders are cautioned that
such forward-looking statements involve risks and uncertainties.
The forward-looking statements contained in the press release speak
only as of the date of the press release, and the Company expressly
disclaims any obligation or undertaking to report any updates or
revisions to any such statement to reflect any change in the
Company’s expectations or any change in events, conditions or
circumstances on which any such statement is based. Certain factors
may cause results to differ materially from those anticipated by
some of the statements made in the press release. Investors are
urged to consider closely the disclosures in our Forms 10-K, 10-Q,
8-K and other filings with the SEC, which can be electronically
accessed from the SEC's website at http://www.sec.gov/.
Corporate contact:
Michael Redman
P: 281-402-3167
E: mredman@oncolixbio.com
Investor contact:
The Ruth Group
Robert Flamm, Ph.D. / Kristin Ko, Ph.D.
P: 646-536-7017 / 7036
E: rflamm@theruthgroup.com / kko@theruthgroup.com